• Hansa Biopharma will present Idefirix post-authorization study results at ASN Kidney Week in Denver on October 23, 2026.
• The late-breaking abstract was selected for an oral presentation in the High-Impact Clinical Trials session at 11:15 a.m. Mountain Time.
• The European study evaluates efficacy and safety in 50 kidney transplants involving imlifidase-treated patients with positive crossmatches against deceased donors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.